Literature DB >> 24229356

High-content assays for hepatotoxicity using induced pluripotent stem cell-derived cells.

Oksana Sirenko1, Jayne Hesley, Ivan Rusyn, Evan F Cromwell.   

Abstract

Development of predictive in vitro assays for early toxicity evaluation is extremely important for improving the drug development process and reducing drug attrition rates during clinical development. High-content imaging-based in vitro toxicity assays are emerging as efficient tools for safety and efficacy testing to improve drug development efficiency. In this report we have used an induced pluripotent stem cell (iPSC)-derived hepatocyte cell model having a primary tissue-like phenotype, unlimited availability, and the potential to compare cells from different individuals. We examined a number of assays and phenotypic markers and developed automated screening methods for assessing multiparameter readouts of general and mechanism-specific hepatotoxicity. Endpoints assessed were cell viability, nuclear shape, average and integrated cell area, mitochondrial membrane potential, phospholipid accumulation, cytoskeleton integrity, and apoptosis. We assayed compounds with known mechanisms of toxicity and also evaluated a diverse hepatotoxicity library of 240 compounds. We conclude that high-content automated screening assays using iPSC-derived hepatocytes are feasible, provide information about mechanisms of toxicity, and can facilitate the safety assessment of drugs and chemicals.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24229356      PMCID: PMC3934660          DOI: 10.1089/adt.2013.520

Source DB:  PubMed          Journal:  Assay Drug Dev Technol        ISSN: 1540-658X            Impact factor:   1.738


  30 in total

1.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.

Authors: 
Journal:  J Biomol Screen       Date:  1999

Review 2.  Mechanisms of drug-induced liver disease.

Authors:  Basuki K Gunawan; Neil Kaplowitz
Journal:  Clin Liver Dis       Date:  2007-08       Impact factor: 6.126

3.  High-content screening: a decade of evolution.

Authors:  Nick Thomas
Journal:  J Biomol Screen       Date:  2009-12-11

4.  Toxicology for the twenty-first century.

Authors:  Thomas Hartung
Journal:  Nature       Date:  2009-07-09       Impact factor: 49.962

5.  Are in vitro tests suitable for regulatory use?

Authors:  Thomas Hartung; George Daston
Journal:  Toxicol Sci       Date:  2009-07-17       Impact factor: 4.849

Review 6.  New directions in toxicity testing.

Authors:  Daniel Krewski; Margit Westphal; Mustafa Al-Zoughool; Maxine C Croteau; Melvin E Andersen
Journal:  Annu Rev Public Health       Date:  2011       Impact factor: 21.981

7.  High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening.

Authors:  P J O'Brien; W Irwin; D Diaz; E Howard-Cofield; C M Krejsa; M R Slaughter; B Gao; N Kaludercic; A Angeline; P Bernardi; P Brain; C Hougham
Journal:  Arch Toxicol       Date:  2006-04-06       Impact factor: 5.153

8.  The effects of jaspamide on human cardiomyocyte function and cardiac ion channel activity.

Authors:  Karen Schweikart; Liang Guo; Zachary Shuler; Rory Abrams; Eric T Chiao; Kyle L Kolaja; Myrtle Davis
Journal:  Toxicol In Vitro       Date:  2012-12-20       Impact factor: 3.500

Review 9.  Acute liver failure in the United States.

Authors:  William M Lee
Journal:  Semin Liver Dis       Date:  2003-08       Impact factor: 6.115

10.  A toxicology for the 21st century--mapping the road ahead.

Authors:  Thomas Hartung
Journal:  Toxicol Sci       Date:  2009-04-08       Impact factor: 4.849

View more
  33 in total

Review 1.  Human-relevant preclinical in vitro models for studying hepatobiliary development and liver diseases using induced pluripotent stem cells.

Authors:  Pooja Chaudhari; Lipeng Tian; Zhaohui Ye; Yoon-Young Jang
Journal:  Exp Biol Med (Maywood)       Date:  2019-02-26

2.  CRISPR/Cas9‒Mediated Tspo Gene Mutations Lead to Reduced Mitochondrial Membrane Potential and Steroid Formation in MA-10 Mouse Tumor Leydig Cells.

Authors:  Jinjiang Fan; Kevin Wang; Barry Zirkin; Vassilios Papadopoulos
Journal:  Endocrinology       Date:  2018-02-01       Impact factor: 4.736

3.  High-content high-throughput assays for characterizing the viability and morphology of human iPSC-derived neuronal cultures.

Authors:  Oksana Sirenko; Jayne Hesley; Ivan Rusyn; Evan F Cromwell
Journal:  Assay Drug Dev Technol       Date:  2014 Nov-Dec       Impact factor: 1.738

Review 4.  Drug-induced steatohepatitis.

Authors:  Ajit Dash; Robert A Figler; Arun J Sanyal; Brian R Wamhoff
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-10-27       Impact factor: 4.481

5.  Risk Characterization of Environmental Samples Using In Vitro Bioactivity and Polycyclic Aromatic Hydrocarbon Concentrations Data.

Authors:  Zunwei Chen; Dillon Lloyd; Yi-Hui Zhou; Weihsueh A Chiu; Fred A Wright; Ivan Rusyn
Journal:  Toxicol Sci       Date:  2021-01-06       Impact factor: 4.849

Review 6.  Liver diseases in the dish: iPSC and organoids as a new approach to modeling liver diseases.

Authors:  Romina Fiorotto; Mariangela Amenduni; Valeria Mariotti; Luca Fabris; Carlo Spirli; Mario Strazzabosco
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-09-05       Impact factor: 5.187

Review 7.  Stem cell-derived liver cells for drug testing and disease modeling.

Authors:  Matthew D Davidson; Brenton R Ware; Salman R Khetani
Journal:  Discov Med       Date:  2015-05       Impact factor: 2.970

Review 8.  iPSC modeling of rare pediatric disorders.

Authors:  Bethany A Freel; Jordan N Sheets; Kevin R Francis
Journal:  J Neurosci Methods       Date:  2019-12-04       Impact factor: 2.390

Review 9.  A shift in paradigm towards human biology-based systems for cholestatic-liver diseases.

Authors:  Fozia Noor
Journal:  J Physiol       Date:  2015-11-04       Impact factor: 5.182

Review 10.  Pluripotent Stem Cell Platforms for Drug Discovery.

Authors:  Kevin G Chen; Barbara S Mallon; Kyeyoon Park; Pamela G Robey; Ronald D G McKay; Michael M Gottesman; Wei Zheng
Journal:  Trends Mol Med       Date:  2018-07-11       Impact factor: 11.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.